Dasatinib can be seen as one of the preferred medicines for the procedural treatment of CML-CP (chronic-phase Chronic Myeloid Leukemia) in salvage and frontline settings. It has been observed that 50 mg of Dasatinib is more effective and tolerated than 100 mg of the daily dose. This was concluded after studies of various cases and their responses.
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe